Literature DB >> 2795721

The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.

J Leonard1, C Parrott, A J Buckler-White, W Turner, E K Ross, M A Martin, A B Rabson.   

Abstract

Mutations were introduced into the regulatory sequences in the long terminal repeat of an infectious molecular clone of the human immunodeficiency virus. Viruses in which the NF-kappa B binding sites were deleted or ones in which one or two Sp1 binding sites were mutated still replicated efficiently in human T lymphocytes. A deletion of the two NF-kappa B sites plus the three Sp1 sites or a mutation of the tat-responsive region rendered the virus replication incompetent. Thus, the NF-kappa B sequences are not required for human immunodeficiency virus infectivity; however, a tat-responsive region is essential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795721      PMCID: PMC251138     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

2.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

3.  Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha.

Authors:  T Okamoto; T Matsuyama; S Mori; Y Hamamoto; N Kobayashi; N Yamamoto; S F Josephs; F Wong-Staal; K Shimotohno
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

4.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template.

Authors:  M J Zoller; M Smith
Journal:  DNA       Date:  1984-12

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Quantitation of a simian virus 40 nonhomologous recombination pathway.

Authors:  D L Dorsett; I Keshet; E Winocour
Journal:  J Virol       Date:  1983-10       Impact factor: 5.103

View more
  113 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Modulation of HIV transcription by CD8(+) cells is mediated via multiple elements of the long terminal repeat.

Authors:  D M Maslove; L W Ni; N C Hawley-Foss; A D Badley; K F Copeland
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.

Authors:  C Van Lint; C A Amella; S Emiliani; M John; T Jie; E Verdin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription.

Authors:  P Dasgupta; P Saikumar; C D Reddy; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

6.  PU.1 binding to ets motifs within the equine infectious anemia virus long terminal repeat (LTR) enhancer: regulation of LTR activity and virus replication in macrophages.

Authors:  Robert Hines; Brenda R Sorensen; Madeline A Shea; Wendy Maury
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Nuclear factors that bind two regions important to transcriptional activity of the simian immunodeficiency virus long terminal repeat.

Authors:  S Winandy; B Renjifo; Y Li; N Hopkins
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Probing protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1 by in vivo footprinting.

Authors:  F Demarchi; P D'Agaro; A Falaschi; M Giacca
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.